title: [Pharmacology of cannabinoid receptors].
abstract: The endocannabinoid (EC) system is a physiological system with an important regulatory role in numerous biological functions, both centrally and peripherally. In certain conditions it can become hyperactive and induce a variety of disorders. The system has two receptor types, designated CB1 and CB2 (present respectively in the CNS and the periphery), as well as endogenous ligands (AEA and 2-AG) and equipment for transporting, synthesizing and degrading them. The discovery of specific CB1 antagonists has opened up interesting new possibilities for the treatment of obesity, diabetes and cardiometabolic risk factors.
authors.affiliation: Sanofi-Aventis, Paris.
authors.forename: Gérard
authors.initials: G
authors.lastname: Le Fur
authors.forename: Murielle
authors.initials: M
authors.lastname: Rinaldi-Carmona
authors.forename: Francis
authors.initials: F
authors.lastname: Barth
authors.forename: John
authors.initials: J
authors.lastname: Alexander
mesh_terms: D000818:Animals; D001069:Appetite Regulation / Q000187:drug effects; D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators / Q000627:therapeutic use; D002186:Cannabinoids / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D017326:Clinical Trials, Phase III as Topic; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004195:Disease Models, Animal; D050171:Dyslipidemias / Q000188:drug therapy; D006801:Humans; D008024:Ligands; D051379:Mice; D018345:Mice, Knockout; D009765:Obesity / Q000188:drug therapy*; D010880:Piperidines / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D011720:Pyrazoles / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D051381:Rats; D043884:Receptor, Cannabinoid, CB1 / Q000037:antagonists & inhibitors; D043885:Receptor, Cannabinoid, CB2 / Q000187:drug effects / Q000502:physiology; D043882:Receptors, Cannabinoid / Q000187:drug effects / Q000502:physiology; D000077285:Rimonabant; D012307:Risk Factors
chemical_list: D063387:Cannabinoid Receptor Antagonists; D063385:Cannabinoid Receptor Modulators; D002186:Cannabinoids; D008024:Ligands; D010880:Piperidines; D011720:Pyrazoles; D043884:Receptor, Cannabinoid, CB1; D043885:Receptor, Cannabinoid, CB2; D043882:Receptors, Cannabinoid; D000077285:Rimonabant